To advance this critical area of medical research, Biocytogen has developed humanized mouse models targeting sugar and lipid metabolism, which are applicable to a range of conditions, including diabetes, obesity, fatty liver disease, fibrosis, and arteriosclerosis. Based on wild-type or target-humanized mice, we can also offer chemical or diet-induced mouse models for pharmacological studies.
on this page
Metabolic diseases are a major threat to health in the modern world. Animal models of metabolic diseases have shown great advantages in the preclinical studies for the mechanisms of drug action, understanding the efficacy and toxicity of existing therapies, screening for new treatments and pursuing personalized therapies. The animal models for metabolic diseases include obesity, diabetes mellitus, liver and cardiovascular disease.
To advance this critical area of medical research, Biocytogen has developed humanized mouse models targeting sugar and lipid metabolism, which are applicable to a range of conditions, including diabetes, obesity, fatty liver disease, fibrosis, and arteriosclerosis. Based on wild-type or target-humanized mice, we can also offer chemical or diet-induced mouse models for pharmacological studies.
DIO, spontaneous, and induced diabetes models are used to evaluate new therapies.
Learn More
GAN diet / GAN+CCL4 induced NASH mouse model, HFMCD-induced NASH mouse model, and the STAM-NASH mouse model
Learn More
In vivo liver fibrosis models provide deeper insights into the disease and help identify potential therapeutics.
Learn More
APAP-induced and Con A-induced acute liver injury model are crucial for investigating disease mechanisms and testing new therapeutics.
Learn More
Humanized mice targeting lipid metabolism and disease models are utilized for testing novel therapeutics and investigating disease mechanisms.
Learn More
A hyperuricemia model induced by potassium oxonate and uric acid is widely used to study the pathogenesis of hyperuricemia and assess the drug efficacy.
Learn More